Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
about
Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatmentUpdate on treatment of light chain amyloidosisSensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissueImmunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses.Light chain amyloidosis 2012: a new era.Pomalidomide: first global approval.Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma.New insights and modern treatment of AL amyloidosis.Immunoglobulin light chain amyloidosis.Pathophysiology and treatment of cardiac amyloidosis.A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.Emerging Advances in the Management of Cardiac Amyloidosis.Attitudes about when and how to treat patients with AL amyloidosis: an international survey.Recent advances in the management of AL Amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.Novel pharmacotherapies for cardiac amyloidosis.New and developing therapies for AL amyloidosis.Systemic amyloidosis: novel therapies and role of biomarkers.Disease burden of systemic light-chain amyloidosis: a systematic literature review.Newer Therapies for Amyloid Cardiomyopathy.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Primarily isolated hepatic involvement of amyloidosis: A case report and overview.Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.Progressive refractory light chain amyloidosis and multiple myeloma patients are responsive to the addition of clarithromycin to IMiD based therapy.Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.New concepts in the treatment and diagnosis of amyloidosis.Light Chain Amyloidosis.Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosisImmunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.Novel Therapies in Light Chain Amyloidosis.
P2860
Q26827340-CB630EBC-1053-4358-BA0D-FEE2EB596088Q26829735-3375E83D-55B5-4748-B70B-2E501435EC79Q33459422-EA54EC00-D68C-408E-A9A4-E9B216547669Q34448455-B1944617-C965-4688-B8C1-00F6DD01E70FQ37619631-DF01B1F9-8A9F-4073-8CAE-829AB1F1C178Q38072108-A2B19478-FFE1-4338-B63E-B24BA196B48CQ38097747-AC42F0CF-30A5-4028-AEAA-9D025F6B9C50Q38130301-95136F0A-E28B-4DF2-8E71-14C3596BFD3EQ38136576-6F4BB4B0-98EE-445B-80AF-8BC7266408C2Q38172295-290E4742-882D-40BD-9C65-4A367FFC1A72Q38259728-68933902-4315-446A-BD10-3EDCAB8F0714Q38411566-A78A0999-A79F-4B8A-A18F-12856280D00FQ38587648-28E04161-23B5-4144-9097-F294A677AF4DQ38600436-49204900-9A30-4140-AF6A-F01274637E77Q38613822-163F369B-796E-4CA8-822D-9BB7191AE09BQ38614967-A116BE41-196D-4654-B2D1-45E623F73594Q38709793-1F06E955-7D49-4DA4-A678-82DD4551DE00Q38779623-0004FE9F-9EDF-4DEC-A6F8-F3DE0A21A267Q38829923-5B265735-41E2-42D8-A642-139BD259EAD7Q38917828-E8152742-7D74-4CE7-A80F-57986454E02AQ38920614-321B49D6-6A5B-4B06-AE24-CB173BB5782EQ38928383-11CA1CD4-CB3C-4366-8E36-323D87F04511Q39062223-8622AEFA-4DD0-42D2-88E0-43B9A87F22A7Q40287459-B0BB466A-135A-46BD-8E16-62E8B3D2F41FQ40470311-F5FAC060-2851-48DC-A355-41470379C2FFQ46463218-03671A83-1820-43E3-B3A3-F89B91A6EB93Q47561519-636EC80F-8E91-447B-BAD6-6B936FB5912CQ52659305-7B203338-FE4C-42DC-B61D-081A82FA3504Q52716575-DAFB923C-A268-41C1-98F3-1AB801482887Q55023498-F9D3B212-01CD-459A-9E87-CC8236B46D6FQ55127439-6502879E-AD03-4796-847A-656A6675248D
P2860
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
@ast
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
@en
type
label
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
@ast
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
@en
prefLabel
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
@ast
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
@en
P2093
P2860
P50
P1433
P1476
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
@en
P2093
A Keith Stewart
Betsy LaPlant
Craig Reeder
Francis Buadi
John A Lust
Joseph R Mikhael
Kristina Laumann
P Lief Bergsagel
Rafael Fonseca
Robert Hall
P2860
P304
P356
10.1182/BLOOD-2012-02-413161
P407
P50
P577
2012-04-04T00:00:00Z